Co-Diagnostics Q3 net loss narrows to $5.9M; announces JV in Saudi Arabia and SPAC exploration for India unit

Co-Diagnostics, Inc.

2025-Q3 EPS reported -$0.62 revenue$358,567

Revenue $0.1M, down from $0.6M YoY; net loss $5.9M ($0.16/share) vs $9.7M ($0.32) in Q3 2024.
Operating loss $7.0M vs $10.2M; adjusted EBITDA loss $6.3M.
Cash and marketable securities $11.4M at Sept 30, 2025.
Signed JV with Arabian Eagle Manufacturing for CoMira Diagnostics in KSA and 18 MENA nations.
Engaged Maxim Group to pursue SPAC transaction for CoSara India JV; closed RDOs totaling ~$10.8M gross.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.